Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05678959




Registration number
NCT05678959
Ethics application status
Date submitted
9/01/2023
Date registered
10/01/2023
Date last updated
22/05/2024

Titles & IDs
Public title
Long-term Extension Study of Ligelizumab in Food Allergy
Scientific title
A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy
Secondary ID [1] 0 0
2022-502366-25
Secondary ID [2] 0 0
CQGE031G12303B
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Food Allergy 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Allergies

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ligelizumab 120 mg
Treatment: Drugs - Ligelizumab 240 mg

Experimental: Ligelizumab 120 mg - 120 mg

Experimental: Ligelizumab 240 mg - 240 mg


Treatment: Drugs: Ligelizumab 120 mg
1 injection of 1.0 mL ligelizumab and 1 injection of 1.0 mL placebo

Treatment: Drugs: Ligelizumab 240 mg
2 injections of 1.0 mL ligelizumab
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of treatment-emergent AEs and SAEs
Timepoint [1] 0 0
Up to 172 weeks
Secondary outcome [1] 0 0
Number of participants tolerating a single dose of more than or equal to 600 mg of peanut protein without dose-limiting symptoms
Timepoint [1] 0 0
Day 1, Week 52, Week 104, Week 156
Secondary outcome [2] 0 0
Number of treatment emergent AEs and SAEs
Timepoint [2] 0 0
Up to 172 weeks
Secondary outcome [3] 0 0
Scores in the Food Allergy Quality of Life Questionnaire (FAQLQ) by age and responder
Timepoint [3] 0 0
Day 1, 10 days before and 3 days after Week 52, 10 days before and 3 days after Week 104, 10 days before and 3 days after Week 156
Secondary outcome [4] 0 0
Scores in the Food Allergy Independent Measure (FAIM) by age and responder
Timepoint [4] 0 0
Day 1, 10 days before and 3 days after Week 52, 10 days before and 3 days after Week 104, 10 days before and 3 days after Week 156
Secondary outcome [5] 0 0
Scores in the Medical Outcomes Study 36-item Short Form Version 2 Acute Version (SF36v2) by age and responder
Timepoint [5] 0 0
Day 1, 10 days before and 3 days after Week 52, 10 days before and 3 days after Week 104, 10 days before and 3 days after Week 156

Eligibility
Key inclusion criteria
- Signed informed consent and assent form (where applicable)

- Participants have completed the treatment period in any ligelizumab Phase III studies
in food allergy

- Participants are willing to adhere to the study visits and procedures, including
receiving injections and participating in the oral food challenge

- Participants agree to continue avoiding exposure to allergens (per core study) and any
other foods they are allergic to throughout the study

- Participants are able to safety continue into the study as judged by the investigator
Minimum age
6 Years
Maximum age
57 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Development of a severe or life threatening episode of an allergic reaction that
required intubation and/or Intensive Care Unit admission during the core studies

- Development of a serious adverse event which is suspected to be related to the study
treatment judged by the investigator during the core studies

- Development of uncontrolled asthma during the core study that could compromise the
safety of participants judged by the investigator

- Development of clinically significant cardiovascular, neurological, and or psychiatric
conditions during the core study that could interfere with or compromise the safety of
the participants, interfere with evaluation or interpretation of the study results or
preclude completion of the study judged by the investigator

- Participants who failed to comply with the protocol requirements and procedures
duringthe core study, and in the Investigator's opinion they should not participate in
this extension study

- Platelets <75,000/ul at end of treatment of the core study

Other protocol defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/04/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
6/07/2027
Actual
Sample size
Target
550
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC,WA
Recruitment hospital [1] 0 0
Novartis Investigative Site - Brisbane
Recruitment hospital [2] 0 0
Novartis Investigative Site - Parkville
Recruitment hospital [3] 0 0
Novartis Investigative Site - Nedlands
Recruitment postcode(s) [1] 0 0
4101 - Brisbane
Recruitment postcode(s) [2] 0 0
3052 - Parkville
Recruitment postcode(s) [3] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Pennsylvania
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
Canada
State/province [20] 0 0
Ontario
Country [21] 0 0
Canada
State/province [21] 0 0
Quebec
Country [22] 0 0
France
State/province [22] 0 0
Angers
Country [23] 0 0
France
State/province [23] 0 0
Lille
Country [24] 0 0
France
State/province [24] 0 0
Toulouse
Country [25] 0 0
France
State/province [25] 0 0
Vandoeuvre Les Nancy
Country [26] 0 0
Germany
State/province [26] 0 0
Berlin
Country [27] 0 0
Germany
State/province [27] 0 0
Dresden
Country [28] 0 0
Germany
State/province [28] 0 0
Frankfurt
Country [29] 0 0
Italy
State/province [29] 0 0
PD
Country [30] 0 0
Japan
State/province [30] 0 0
Kanagawa
Country [31] 0 0
Japan
State/province [31] 0 0
Tokyo
Country [32] 0 0
Netherlands
State/province [32] 0 0
Utrecht
Country [33] 0 0
Spain
State/province [33] 0 0
Barcelona
Country [34] 0 0
Spain
State/province [34] 0 0
Catalunya
Country [35] 0 0
Spain
State/province [35] 0 0
Madrid

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is an extension study to evaluate the long-term safety and efficacy of ligelizumab in
particiants who have completed a ligelizumab Phase III study in food allergy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05678959
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Country 0 0
Phone 0 0
1-888-669-6682
Fax 0 0
Email 0 0
novartis.email@novartis.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05678959